Novel mitochondrial metabolism inhibitors for aggressive and treatment-resistant MYC-high breast cancers

The Defense Health Agency awarded Helsingin Yliopisto (University of Helsinki) $879,495 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel mitochondrial metabolism inhibitors targeting aggressive and treatment-resistant MYC-high breast cancers. The award funds basic and translational research conducted in Finland through May 31, 2029. The University of Helsinki, a Finnish state-controlled research institution, serves as the prime recipient and performs the research work directly. The Military Medical Research and Development program supports biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions applicable to military contexts. Awards under this program typically range from $100,000 to $20 million for consortia, with an average project period of three to four years.